Search

Journal Cephalalgia

41. A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood. (January 2015)

Authors:
Weller, Claudia M; Leen, Wilhelmina G; Neville, Brian GR; Duncan, John S; Vries, Boukje de; Geilenkirchen, Marije A; Haan, Joost; Kamsteeg, Erik-Jan; Ferrari, Michel D; Maagdenberg, Arn MJM van den; Willemsen, Michèl AAP; Scheffer, Hans; Terwindt, Gisela M
Journal:
Cephalalgia
Issue:
Volume 35:Number 1(2015)
Page Start:
10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

42. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. (March 2021)

Authors:
Kopruszinski, Caroline M; Navratilova, Edita; Swiokla, Juliana; Dodick, David W; Chessell, Iain P; Porreca, Frank
Journal:
Cephalalgia
Issue:
Volume 41:Number 3(2021)
Page Start:
305
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

45. A patient with pulmonary arteriovenous fistulas (P-AVFs) in whom migraine disappeared after transcatheter coil embolization for the secondary prevention of paradoxical infarction. A case report. (March 2017)

Authors:
Kakehi, Yoshiaki; Takahashi, Nobuyuki; Miyazaki, Masayuki; Shimizu, Hisao; Nagami, Shuhei; Kohyama, Shinya; Yamane, Fumitaka; Ishihara, Shoichiro
Journal:
Cephalalgia
Issue:
Volume 37:Number 3(2017)
Page Start:
294
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

47. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. (November 2018)

Authors:
Cohen-Barak, Orit; Weiss, Sivan; Rasamoelisolo, Michele; Faulhaber, Nicola; Yeung, Paul P; Loupe, Pippa S; Yoon, Esther; Gandhi, Mohit D; Spiegelstein, Ofer; Aycardi, Ernesto
Journal:
Cephalalgia
Issue:
Volume 38:Number 13(2018)
Page Start:
1960
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

48. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. (January 2021)

Authors:
Ashina, Messoud; Doležil, David; Bonner, Jo H; Zhou, Lifen; Klatt, Jan; Picard, Hernan; Mikol, Daniel D
Journal:
Cephalalgia
Issue:
Volume 41:Number 1(2021)
Page Start:
33
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗